Lymphoma, B-Cell, Marginal Zone: all 428 studies
Page 1 of 5. Open to participants first (108), then studies with results posted, then the rest; newest registration first within each.
- Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin LymphomaRecruitingNCT07763210Phase 2
- A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin LymphomasNot yet recruitingNCT07713459Phase 2
- Atrial Fibrillation Among Patients With Hematologic Malignancies on Tyrosine Kinase Inhibitor TherapyNot yet recruitingNCT07711327
- A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue Extranodal Marginal Zone LymphomaNot yet recruitingNCT07705308Phase 2
- A Study of ARC-02 in B-cell NHLRecruitingNCT07691606Phase 1
- Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone LymphomaNot yet recruitingNCT07654465Phase 2
- Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't Get Better With TreatmentNot yet recruitingNCT07638722Phase 2
- Pomalidomide Plus Anti-CD20 Antibody and Prednisone in Frontline Indolent B-Cell LymphomaNot yet recruitingNCT07609446
- Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK InhibitorsNot yet recruitingNCT07592481Not applicable
- Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone LymphomaRecruitingNCT07583810Phase 2
- Cognitive Impairment in Patients Undergoing Cell- and Antibody-based Immunotherapies for Haematological Malignancies: The COGNITOX StudyNot yet recruitingNCT07558057
- Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT LymphomaRecruitingNCT07554898Phase 2
- A Study to Evaluate MTM-H-001 Injection in Adult Participants With Relapsed or Refractory B-cell MalignanciesNot yet recruitingNCT07476378Not applicable
- Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZLRecruitingNCT07448324Phase 2
- Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZLRecruitingNCT07441993Phase 2
- A Study of APG-3288 in Relapsed/Refractory Blood CancersRecruitingNCT07424833Phase 1
- Molecular and Cellular Characterization of MALT LymphomaNot yet recruitingNCT07376330
- Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL.RecruitingNCT07372365Phase 2
- Application of Orelabrutinib With or Without CD20 Monoclonal Antibody in Previously Untreated Marginal Zone LymphomaRecruitingNCT07355699Phase 4
- Zanubrutinib, Rituximab, and Lenalidomide in the First-Line Treatment of Marginal Zone LymphomaNot yet recruitingNCT07299331Not applicable
- Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of LymphomaRecruitingNCT07249905Phase 1/2
- Zanubrutinib Combined With Rituximab in the Treatment for Patients With Marginal Zone LymphomaRecruitingNCT07233720
- A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL)RecruitingNCT07231952Phase 2
- Rituximab (Rtx) + Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma (NHL)RecruitingNCT07225439Phase 1
- Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZLRecruitingNCT07208981Phase 2
- Watch and Wait or Worry and Wait in Indolent LymphomaEnrolling by invitationNCT07173790
- CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell LymphomasEnrolling by invitationNCT07168486Phase 1
- Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT LymphomaNot yet recruitingNCT07144657Phase 2
- This is a Phase 1 Study to Evaluate the Safety of LTZ-301 in Patients With Non-Hodgkin LymphomaRecruitingNCT07121946Phase 1
- A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )RecruitingNCT07101328Phase 1
- A Study of Reduced Dose Radiation Therapy for People With B-Cell LymphomasRecruitingNCT07029217Phase 3
- JWCAR239 in Patients With B Cell Non-Hodgkin LymphomaNot yet recruitingNCT07024147Phase 1
- Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone LymphomaRecruitingNCT07022223Phase 2
- BR Combined With OR in Treatment-naïve Marginal Zone LymphomaNot yet recruitingNCT07008053Phase 2
- A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström MacroglobulinemiaRecruitingNCT06986174Phase 2
- Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT06980116Phase 1
- Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or Refractory Large B-cell LymphomaRecruitingNCT06905509Phase 2
- Combating Cancer-Related Fatigue: A Personalized Supportive Care ProgramRecruitingNCT06860880Not applicable
- Zanubrutinib in Combination With Sonrotoclax for the Treatment of Underrepresented Ethnic and Racial Minorities With Relapsed or Refractory B-cell Non-Hodgkin LymphomaRecruitingNCT06859008Phase 1
- Study to Assess Effectiveness and Safety of Zanubrutinib for Patients with Marginal Zone Lymphoma Treated in Italy Under the Named Patient Program (NPP)RecruitingNCT06823960
- Study to Assess Clinical Characteristics and Outcome of Patients with Marginal Zone LymphomasRecruitingNCT06806488
- Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL)RecruitingNCT06796998Phase 2
- MZL-IPI Risk-adapted Targeted Therapy in Untreated MZLRecruitingNCT06793189Phase 2
- HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZLRecruitingNCT06792825Phase 2
- Q702 for the Treatment of Patients With Hematologic MalignanciesRecruitingNCT06712810Phase 1
- A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell MalignanciesRecruitingNCT06708897Phase 1
- Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II TrialRecruitingNCT06700798Phase 2
- Linperlisib Combination With Obinutuzumab Frontline Treatment of Marginal Zone Lymphoma Patients (MZL)RecruitingNCT06592170Phase 1/2
- Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone LymphomaRecruitingNCT06566807Phase 2
- Epco, Zanu, Ritux for R/R FL or MZLRecruitingNCT06563596Phase 2
- SynKIR-310 for Relapsed/Refractory B-NHLRecruitingNCT06544265Phase 1
- Registry Study of Chinese Patients with Marginal Zone Lymphoma (MOTIVE)RecruitingNCT06534463
- Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)RecruitingNCT06533579Phase 1/2
- Combination of Orelabrutinib and Obinutuzumab in Untreated Marginal Zone LymphomasRecruitingNCT06513234Phase 2
- Rituximab Plus Venetoclax in Front Line Marginal Zone LymphomaRecruitingNCT06510309Phase 2
- Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL)RecruitingNCT06504940Phase 2
- The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyRecruitingNCT06503276Phase 2
- Prospective Clinical Study of Orelabrutinib in Combination With Rituximab (OR) for Primary Marginal Zone Lymphoma (MZL) That Failed or Not Suitable for Local TherapyRecruitingNCT06478472Not applicable
- Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
- A Cohort Study in Newly Diagnosed MZLRecruitingNCT06449885
- Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingNCT06390956Phase 2
- Rituximab and Zanubrutinib in Patients With Indolent B-cell LymphomasRecruitingNCT06350318Phase 2
- AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell LymphomasRecruitingNCT06340737Phase 1
- Orelabrutinib in the Treatment of HP-positive Gastric MALT LymphomaRecruitingNCT06228963Phase 2
- Preliminary Assessment of [18F]BL40 in PET/CT ScansRecruitingNCT06224309
- B-Cell Activating Factor Receptor (BAFFR)-Based Chimeric Antigen Receptor T-Cells With Fludarabine and Cyclophosphamide Lymphodepletion for the Treatment of Relapsed or Refractory B-cell Hematologic MalignanciesRecruitingNCT06191887Phase 1
- Evaluation of Hypertension Management and Cardiovascular Adverse Event Prevention in Patients With B-cell Malignancies Undergoing Treatment With Bruton Tyrosine Kinase Inhibitors, the HALT StudyRecruitingNCT06151730
- A Trial to Find Out if Odronextamab Combined With Lenalidomide is Safe and Works Better Than Rituximab Combined With Lenalidomide in Adult Participants With Follicular Lymphoma and Marginal Zone LymphomaRecruitingNCT06149286Phase 3
- Clinical Study of OR for Second-line Treatment of Refractory MZLRecruitingNCT06134284Phase 4
- Efficacy and Safety of Orelabrutinib Combined With Rituximab Versus Lenalidomide Combined With Rituximab in Patients With Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT06082102Phase 3
- RCT of Intralesional Rituximab Injection Versus Involved Site Radiation Therapy in Ocular Adnexal MALT LymphomaNot yet recruitingNCT06064344Not applicable
- Registry Platform Hematologic Malignancies (RUBIN) - Extension of Tumor Registry Lymphatic NeoplasmsRecruitingNCT06043011
- CD79b-19 CAR T Cells in Non-Hodgkin LymphomaRecruitingNCT06026319Phase 1
- Mosunetuzumab-Lenalidomide Versus Investigator Choices in Patients With Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT06006117Phase 3
- LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell MalignanciesRecruitingNCT05990465Phase 1
- A Retrospective Study on Extranodal Lymphoma or Lymphoma of Rare Pathological TypesNot yet recruitingNCT05907447
- Obinutuzumab in Combination With Lenalidomide in Relapsed or Refractory Marginal Zone LymphomaRecruitingNCT05846750Phase 2
- Allo HSCT Using RIC and PTCy for Hematological DiseasesRecruitingNCT05805605Phase 2
- A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell MalignanciesRecruitingNCT05780034Phase 1
- Early Detection and Screening of Hematological Malignancies - SANGUINERecruitingNCT05735704
- Integrated Molecular and Clinical Profiling to Improve Disease Characterization and Outcome Prediction in Nodal Marginal Zone LymphomaRecruitingNCT05700149
- A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell MalignanciesRecruitingNCT05643742Phase 1/2
- AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin LymphomaRecruitingNCT05602363Phase 1
- Study of SGR-1505 in Mature B-Cell NeoplasmsRecruitingNCT05544019Phase 1
- Zanubrutinib in Patients With Waldenström's Macroglobulinemia, Chronic Lymphocytic Leukemia, Marginal Zone Lymphoma and Follicular LymphomaRecruitingNCT05326308
- Open-label of Loncastuximab Tesirine (ADCT-402) in Relapsed/Refractory Marginal Zone LymphomaRecruitingNCT05296070Phase 2
- Treatment of Chinese Participants With B-Cell Malignancies With BGB-16673, a Bruton Tyrosine Kinase-Targeted Protein-DegraderRecruitingNCT05294731Phase 1/2
- A Study of NX-5948 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT05131022Phase 1
- A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell MalignanciesRecruitingNCT05006716Phase 1/2
- Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin LymphomasRecruitingNCT04883437Phase 2
- Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaRecruitingNCT04840602Phase 2
- MIL62 Combined With Lenalidomide Versus Lenalidomide for Patients With Rituximab Refractory Follicular LymphomaRecruitingNCT04834024Phase 3
- A Study of NX-2127 in Adults With Relapsed/Refractory B-cell MalignanciesRecruitingNCT04830137Phase 1
- Mosunetuzumab With Lenalidomide Augmentation as First-line Therapy for Follicular and Marginal Zone LymphomaRecruitingNCT04792502Phase 2
- Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.RecruitingNCT04775745Phase 1
- A Novel Vaccine (EO2463) as Monotherapy and in Combination, for Treatment of Patients With Indolent Non-Hodgkin LymphomaRecruitingNCT04669171Phase 1/2
- Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin LymphomaRecruitingNCT04545762Phase 1
- Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin LymphomaRecruitingNCT04491370Phase 1/2
- Study of Kappa Chimeric Antigen Receptor (CAR) T Lymphocytes Co-Expressing the Kappa and CD28 CARs for Relapsed/Refractory Kappa+ Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.RecruitingNCT04223765Phase 1
- Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological MalignanciesRecruitingNCT04195633Phase 2